Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
Authors:
- Maria Libera AsciertoMAMaria Libera Ascierto
- Andrea WorschechAWAndrea Worschech
- Zhiya YuZYZhiya Yu
- Sharon AdamsSASharon Adams
- Jennifer ReinbothJRJennifer Reinboth
- Nanhai G ChenNCNanhai G Chen
- Zoltan PosZPZoltan Pos
- Rahul RoychoudhuriRRRahul Roychoudhuri
- Giovanni Di PasqualeGPGiovanni Di Pasquale
- Davide BedognettiDBDavide Bedognetti
- Lorenzo UccelliniLULorenzo Uccellini
- Fabio RossanoFRFabio Rossano
Open Access
- 19 October 2011
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 1-14
Abstract
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo. In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection. We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection. Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.Keywords
This publication has 36 references indexed in Scilit:
- Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infectionBMC Cancer, 2011
- Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SACancer Gene Therapy, 2010
- Integrin αvβ5 is a primary receptor for adenovirus in CAR-negative cellsVirology Journal, 2010
- Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapyJournal of Translational Medicine, 2010
- Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapyBMC Genomics, 2009
- Oncolytic vaccinia therapy of squamous cell carcinomaMolecular Cancer, 2009
- Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic AdenovirusesCancer Research, 2009
- The immunologic aspects of poxvirus oncolytic therapyCancer Immunology, Immunotherapy, 2009
- Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural MesotheliomaHuman Gene Therapy, 2008
- Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panelMolecular Cancer Therapeutics, 2006